🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
IceCure Medical Ltd (ICCM)
NASDAQ: ICCM Β· Real-Time Price Β· USD
0.8300
-0.1671 (-16.76%)
Nov 20, 2026, 11:59 AM EST - Market open

IceCure Medical Earnings Call Transcripts

Fiscal Year 2026

  • 9M revenue grew 26% and U.S. sales rose 83%, alongside wider commercial reach and ChoICE progress. Losses increased, while management projected healthy double-digit 2027 revenue growth and flagged possible delay to the study’s 400-patient timeline.

  • Revenue grew 45% year-over-year to $1.8M, driven by increased physician adoption and a 70% rise in the U.S. install base. Gross margin improved to 30%, and cash reserves reached $12M after new financing. The ChoICE Study and international expansion continue to support long-term growth.

  • Revenue grew 26% year-over-year in Q1 2026, with strong U.S. and North American performance. FDA clearance for low-risk breast cancer has accelerated adoption, expanded the active account base, and driven global interest, with continued growth and commercial expansion expected.

Fiscal Year 2025

  • Record 2025 revenue of $3.4M was driven by FDA clearance and new guidelines for ProSense, fueling strong U.S. and global adoption. Expansion into Canada and Japan, a 30-site post-marketing study, and reimbursement improvements are expected to accelerate growth.

  • FDA marketing authorization for ProSense positions the company for significant U.S. and global growth, with an addressable market of over 200,000 patients annually. Revenue and gross margin declined year-over-year, but capital raises have strengthened the financial position.

  • Investor Update

    FDA granted marketing authorization for ProSense Cryoablation for low-risk breast cancer in women 70+, making it the first device of its kind. Commercial rollout and a 400-patient post-market study will proceed in parallel, with strong reimbursement and global expansion plans.

  • Regulatory progress continues with FDA review of ProSense and optimism for approval by year-end 2025. Revenue and gross margin declined year-over-year due to shipment delays, but a $10 million rights offering strengthens the cash position for upcoming milestones. Additional traction in Europe and Japan is driven by strong clinical evidence.

  • Q1 2025 saw stable revenue with growth in North America and Europe, offset by declines in Asia. The FDA is reviewing a post-market study plan for ProSense, with commercial launch and expanded reimbursement anticipated upon approval. Cash position was strengthened by a $2M bridge loan and share sales.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022